Cargando…

Tolerating bad health research: the continuing scandal

BACKGROUND: At the 2015 REWARD/EQUATOR conference on research waste, the late Doug Altman revealed that his only regret about his 1994 BMJ paper ‘The scandal of poor medical research’ was that he used the word ‘poor’ rather than ‘bad’. But how much research is bad? And what would improve things? MAI...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirosca, Stefania, Shiely, Frances, Clarke, Mike, Treweek, Shaun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161194/
https://www.ncbi.nlm.nih.gov/pubmed/35655288
http://dx.doi.org/10.1186/s13063-022-06415-5
_version_ 1784719432817311744
author Pirosca, Stefania
Shiely, Frances
Clarke, Mike
Treweek, Shaun
author_facet Pirosca, Stefania
Shiely, Frances
Clarke, Mike
Treweek, Shaun
author_sort Pirosca, Stefania
collection PubMed
description BACKGROUND: At the 2015 REWARD/EQUATOR conference on research waste, the late Doug Altman revealed that his only regret about his 1994 BMJ paper ‘The scandal of poor medical research’ was that he used the word ‘poor’ rather than ‘bad’. But how much research is bad? And what would improve things? MAIN TEXT: We focus on randomised trials and look at scale, participants and cost. We randomly selected up to two quantitative intervention reviews published by all clinical Cochrane Review Groups between May 2020 and April 2021. Data including the risk of bias, number of participants, intervention type and country were extracted for all trials included in selected reviews. High risk of bias trials was classed as bad. The cost of high risk of bias trials was estimated using published estimates of trial cost per participant. We identified 96 reviews authored by 546 reviewers from 49 clinical Cochrane Review Groups that included 1659 trials done in 84 countries. Of the 1640 trials providing risk of bias information, 1013 (62%) were high risk of bias (bad), 494 (30%) unclear and 133 (8%) low risk of bias. Bad trials were spread across all clinical areas and all countries. Well over 220,000 participants (or 56% of all participants) were in bad trials. The low estimate of the cost of bad trials was £726 million; our high estimate was over £8 billion. We have five recommendations: trials should be neither funded (1) nor given ethical approval (2) unless they have a statistician and methodologist; trialists should use a risk of bias tool at design (3); more statisticians and methodologists should be trained and supported (4); there should be more funding into applied methodology research and infrastructure (5). CONCLUSIONS: Most randomised trials are bad and most trial participants will be in one. The research community has tolerated this for decades. This has to stop: we need to put rigour and methodology where it belongs — at the centre of our science. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06415-5.
format Online
Article
Text
id pubmed-9161194
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91611942022-06-02 Tolerating bad health research: the continuing scandal Pirosca, Stefania Shiely, Frances Clarke, Mike Treweek, Shaun Trials Commentary BACKGROUND: At the 2015 REWARD/EQUATOR conference on research waste, the late Doug Altman revealed that his only regret about his 1994 BMJ paper ‘The scandal of poor medical research’ was that he used the word ‘poor’ rather than ‘bad’. But how much research is bad? And what would improve things? MAIN TEXT: We focus on randomised trials and look at scale, participants and cost. We randomly selected up to two quantitative intervention reviews published by all clinical Cochrane Review Groups between May 2020 and April 2021. Data including the risk of bias, number of participants, intervention type and country were extracted for all trials included in selected reviews. High risk of bias trials was classed as bad. The cost of high risk of bias trials was estimated using published estimates of trial cost per participant. We identified 96 reviews authored by 546 reviewers from 49 clinical Cochrane Review Groups that included 1659 trials done in 84 countries. Of the 1640 trials providing risk of bias information, 1013 (62%) were high risk of bias (bad), 494 (30%) unclear and 133 (8%) low risk of bias. Bad trials were spread across all clinical areas and all countries. Well over 220,000 participants (or 56% of all participants) were in bad trials. The low estimate of the cost of bad trials was £726 million; our high estimate was over £8 billion. We have five recommendations: trials should be neither funded (1) nor given ethical approval (2) unless they have a statistician and methodologist; trialists should use a risk of bias tool at design (3); more statisticians and methodologists should be trained and supported (4); there should be more funding into applied methodology research and infrastructure (5). CONCLUSIONS: Most randomised trials are bad and most trial participants will be in one. The research community has tolerated this for decades. This has to stop: we need to put rigour and methodology where it belongs — at the centre of our science. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06415-5. BioMed Central 2022-06-02 /pmc/articles/PMC9161194/ /pubmed/35655288 http://dx.doi.org/10.1186/s13063-022-06415-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Pirosca, Stefania
Shiely, Frances
Clarke, Mike
Treweek, Shaun
Tolerating bad health research: the continuing scandal
title Tolerating bad health research: the continuing scandal
title_full Tolerating bad health research: the continuing scandal
title_fullStr Tolerating bad health research: the continuing scandal
title_full_unstemmed Tolerating bad health research: the continuing scandal
title_short Tolerating bad health research: the continuing scandal
title_sort tolerating bad health research: the continuing scandal
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161194/
https://www.ncbi.nlm.nih.gov/pubmed/35655288
http://dx.doi.org/10.1186/s13063-022-06415-5
work_keys_str_mv AT piroscastefania toleratingbadhealthresearchthecontinuingscandal
AT shielyfrances toleratingbadhealthresearchthecontinuingscandal
AT clarkemike toleratingbadhealthresearchthecontinuingscandal
AT treweekshaun toleratingbadhealthresearchthecontinuingscandal